Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Biliary function and its regulation].

Raoul Poupon1, Nicolas Chignard, Olivier Rosmorduc

  • 1Inserm U.402 et Département d'Hépato-gastroentérologie, Faculté de Médecine Saint-Antoine, Université Pierre et Marie Curie, Paris 6, 27, rue Chaligny, 75571 Paris Cedex 12, France. raoul.poupon@sat.ap-hop-paris.fr

Medecine Sciences : M/S
|December 8, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

ASO Visual Abstract: Is R1 Extended Liver Resection for Locally Advanced Intrahepatic Cholangiocarcinoma Justified? Nodal Status Not Margin Drives Prognosis.

Annals of surgical oncology·2026
Same author

Is R1 Extended Liver Resection for Locally Advanced Intrahepatic Cholangiocarcinoma Justified? Nodal Status Not Margin Drives Prognosis.

Annals of surgical oncology·2026
Same author

Clinical predictors of response to Atezolizumab-bevacizumab in Child-Pugh B patients with hepatocellular carcinoma.

JHEP reports : innovation in hepatology·2026
Same author

Effect of a defatting pharmacologic cocktail with rapamycin during cold-to-warm ex situ perfusion of discarded human livers: A comparative study.

Surgery·2026
Same author

Vessels encapsulating tumor clusters predict better outcomes in advanced hepatocellular carcinoma treated with atezolizumab-bevacizumab.

JHEP reports : innovation in hepatology·2026
Same author

Clec3b⁺ fibroblasts are the primary effectors of portal fibrosis following activation via a KLF4/periostin axis.

Nature communications·2026

Bile formation relies on transporters regulated by bile acids. Understanding these mechanisms explains disease variability and guides new cholestatic liver disease treatments.

Area of Science:

  • Hepatology and Gastroenterology
  • Molecular Biology
  • Physiology

Context:

  • Biliary function is crucial for nutrient absorption, cholesterol balance, and waste elimination.
  • Bile is formed by hepatocytes and modified by cholangiocytes via secretion and absorption.
  • Active transport of bile acids and solutes drives bile formation through osmotic filtration.

Purpose:

  • To review the molecular mechanisms of bile formation and cholestatic liver diseases.
  • To highlight the role of membrane transporters and their regulation by bile acids.
  • To discuss the phenotypic variability in cholestatic diseases and current treatment strategies.

Summary:

  • Membrane transporters, identified through molecular research, are key to bile formation and are regulated by nuclear receptors activated by bile acids.

Related Experiment Videos

  • Monogenic cholestatic diseases underscore the critical role of these transporters.
  • Bile acids modulate transporters, initiating adaptive responses to cholestasis, which influences disease presentation.

    • Impact:

    • Elucidating transporter regulation by bile acids offers insights into cholestatic disease variability.
    • Advances in understanding bile formation pathogenesis pave the way for targeted drug development.
    • This research informs potential new therapies for cholestatic liver diseases beyond current treatments like ursodeoxycholic acid and liver transplantation.